AMENDMENTS TO THE CLAIMS

1. **(Original)** An isolated nucleic acid molecule comprising a sequence selected from the group consisting of:

(a) a sequence provided in SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25;

(b) a complement of a sequence provided in SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25;

(c) a sequence consisting of at least 10 contiguous nucleotides of a sequence provded in SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25 or a complementary form thereof;

(d) a sequence which hybridizes to the complement of a sequence provided in SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25, under conditions of low stringency;

(e) a sequence having at least 70% identify after optimal alignment to a sequence provided in SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25;

(f) a derivative of a sequence provided in SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25; and

(g) a homolog of a sequence provided in SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25.

2. **(Original)** A vector comprising a nucleic acid molecule of Claim 1 operably linked to an expression control sequence.

3. **(Original)** The vector of Claim 2, wherein the vector is an artificial chromosome.

4. **(Original)** The vector of Claim 3, wherein the vector is an artificial human chromosome.

5. **(Previously presented)** A host cell transformed or transfected with the vector of Claim 2.

6. **(Original)** An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) a sequence provided in SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 27 and 28;

(b) a sequence having at least 70% similarity after optimal alignment to an amino acid sequence provided in SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 27 and 28;

(c) a derivative, homolog, analog, chemical equivalent or mimetic of a sequence provided in SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 27 and 28;

(d) a sequence encoded by a nucleic acid molecule of Claim 1; and

(e) a sequence having at least 70% similarity after optimal alignment to a sequence encoded by a nucleic acid molecule of Claim 1.

7. **(Original)** A vector comprising a nucleic acid molecule which encodes a polypeptide of Claim 6 operably linked to an expression control sequence.

8. **(Original)** The vector of Claim 7, wherein the vector is an artificial chromosome.

9. **(Original)** The vector of Claim 8, wherein the vector is a human artificial chromosome.

10. **(Previously presented)** A host cell transformed or transfected with the vector of Claim 7.

11. **(Original)** An isolated immunointeractive molecule which specifically binds to a polypeptide of Claim 6 or an immunogenic fragment thereof.

12. **(Original)** The immunointeractive molecule of Claim 11, wherein the molecule is an antibody or an antigen binding fragment thereof.

13. **(Previously presented)** The isolated antibody of Claim 12, wherein said antibody is selected from the group consisting of: a polyclonal antibody, a monoclonal antibody, a humanized antibody, and a deimmunized antibody.

14. **(Previously presented)** The antibody of Claim 12 conjugated to an immunotoxin.

15. **(Previously presented)** A composition comprising a first component and a second component selected from a pharmaceutical carrier, diluent and an immunostimulant.

16. **(Previously presented)** A method for detecting the presence of a disease or condition in a subject, comprising the steps of:

(a) obtaining a biological sample from said subject;

(b) contacting said biological sample with an molecule that binds to a polypeptide Claim 6;

(c) detecting in said biological sample the presence of binding of said molecule; and

(d) comparing the presence of bound molecule with a pre-determined cut-off value to make a determination as to the presence or absence of a disease or condition in said subject.

17. **(Original)** The method of Claim 16, wherein said disease or condition is AML.

18. **(Original)** The method of Claim 16, wherein said molecule is an antibody.

19-26. **(Canceled)**

27. **(Previously presented)** A composition comprising a first component comprising a polypeptide of Claim 6 and a second component selected from the group consisting of: a pharmaceutical carrier, diluent and an immunostimulant.

28. **(Previously presented)** A composition comprising a first component comprising an immunointeractive molecule of Claim 11 and a second component selected from the group consisting of: a pharmaceutical carrier, diluent and an immunostimulant.

29. **(Previously presented)** A method for detecting the presence of a disease or condition in a subject, comprising the steps of:

(a) obtaining a biological sample from said subject;

(b) contacting said biological sample with an molecule that binds to a nucleic acid molecule of Claim 1;

(c) detecting in said biological sample the presence of binding of said molecule; and

(d) comparing the presence of bound molecule with a pre-determined cut-off value to make a determination as to the presence or absence of a disease or condition in said subject.